MRD in Solid Tumor and Hematological Indications: Today and Tomorrow

Explore the current and future applications of Measurable Residual Disease (MRD) testing in solid tumor and hematological indications through this informative webinar presented by Dr. Bob Holt and Prof. Maria Teresa Voso. Delve into the concept of MRD, which refers to the presence of minute tumor cell populations persisting after treatment. Discover how MRD testing is utilized clinically to identify disease relapse and guide patient treatment strategies. Examine the traditional use of MRD in hematological indications and learn about its expanding role in solid tumor indications, facilitated by advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) based testing. Gain insights into the evolving landscape of MRD applications and their potential impact on cancer management and patient outcomes.